Ki67 targeted strategies for cancer therapy

被引：226

作者：

Yang, C. ^{[1
]}

Zhang, J. ^{[1
]}

Ding, M. ^{[1
,2
]}

Xu, K. ^{[1
,2
]}

Li, L. ^{[1
]}

Mao, L. ^{[1
,2
]}

Zheng, J. ^{[1
]}

机构：

[1] Xuzhou Med Univ, Jiangsu Key Lab Biol Canc Therapy, Xuzhou 221002, Peoples R China

[2] Univ Med Coll, Affiliated Hosp, Dept Urinary Surg, Xuzhou 221000, Peoples R China

来源：

CLINICAL & TRANSLATIONAL ONCOLOGY | 2018年 / 20卷 / 05期

关键词：

Ki67; Gene therapy; Renal cancer; siRNA; Target therapy; Proliferation; PROLIFERATION-ASSOCIATED ANTIGEN; SELECTIVE ADENOVIRUS ONYX-015; SMALL-INTERFERING-RNA; PHASE-I TRIAL; ONCOLYTIC ADENOVIRUS; ANTISENSE OLIGONUCLEOTIDE; PROSTATE-CANCER; BREAST-CANCER; INTRAVENOUS-INFUSION; ANTITUMOR-ACTIVITY;

D O I：

10.1007/s12094-017-1774-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Ki67 is a well-known proliferation marker for the evaluation of cell proliferation. Numerous studies have indicated that Ki67 index independently predicts cancer progression. Moreover, because Ki67 is highly expressed in malignant cells but almost could not be detected in normal cells, it has become a promising target for cancer therapy. In this review, we summarize recent advances in Ki67 targeted cancer therapy. In particular, we highlight recent development on the exploitation of Ki67 promoter to drive the expression of siRNAs or therapeutic genes in cancer cells specifically. The use of Ki67 as an attractive target opens a new avenue for cancer therapy.

引用

页码：570 / 575

页数：6

共 50 条

[21] A Scoring Method for Immunohistochemical Staining on Ki67
Guo, Rui
Ma, Li
Bai, Xiomei
Miao, Li
Li, Zongfang
Yang, Jun
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2021, 29 (03) : E20 - E28
[22] The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer
Jones, Robin L.
Salter, Janine
A'Hern, Roger
Nerurkar, Ash
Parton, Marina
Reis-Filho, Jorge S.
Smith, Ian E.
Dowsett, Mitchell
BREAST CANCER RESEARCH AND TREATMENT, 2009, 116 (01) : 53 - 68
[23] An International Ki67 Reproducibility Study
Polley, Mei-Yin C.
Leung, Samuel C. Y.
McShane, Lisa M.
Gao, Dongxia
Hugh, Judith C.
Mastropasqua, Mauro G.
Viale, Giuseppe
Zabaglo, Lila A.
Penault-Llorca, Frdrique
Bartlett, John M. S.
Gown, Allen M.
Symmans, W. Fraser
Piper, Tammy
Mehl, Erika
Enos, Rebecca A.
Hayes, Daniel F.
Dowsett, Mitch
Nielsen, Torsten O.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2013, 105 (24): : 1897 - 1906
[24] Is Ki67 prognostic for aggressive prostate cancer? A multicenter real-world study
Fantony, Joseph J.
Howard, Lauren E.
Csizmadi, Ilona
Armstrong, Andrew J.
Lark, Amy L.
Galet, Colette
Aronson, William J.
Freedland, Stephen J.
BIOMARKERS IN MEDICINE, 2018, 12 (07) : 727 - 736
[25] Interobserver concordance of Ki67 labeling index in breast cancer: Japan Breast Cancer Research Group Ki67 Ring Study
Mikami, Yoshiki
Ueno, Takayuki
Yoshimura, Kenichi
Tsuda, Hitoshi
Kurosumi, Masafumi
Masuda, Shinobu
Horii, Rie
Toi, Masakazu
Sasano, Hironobu
CANCER SCIENCE, 2013, 104 (11) : 1539 - 1543
[26] An Interobserver Reproducibility Analysis of Ki67 Visual Assessment in Breast Cancer
Shui, Ruohong
Yu, Baohua
Bi, Rui
Yang, Fei
Yang, Wentao
PLOS ONE, 2015, 10 (05):
[27] Association between Ki67 expression and therapeutic outcome in colon cancer
Liu, Qi
Ran, Dongmei
Wang, Liping
Feng, Jiajun
Deng, Wei
Mei, Dongdong
Peng, Yifan
Du, Changzheng
ONCOLOGY LETTERS, 2023, 25 (06)
[28] Ki67 in breast cancer: prognostic and predictive potential
Yerushalmi, Rinat
Woods, Ryan
Ravdin, Peter M.
Hayes, Malcolm M.
Gelmon, Karen A.
LANCET ONCOLOGY, 2010, 11 (02) : 174 - 183
[29] Factors Predicting Response in Breast Cancer Receiving Neoadjuvant Therapy and the Role of Ki67 Labeling Index
Ekinci, Ferhat
Uzun, Mehmet
Demir, Bilgin
Unek, Ilkay Tugba
Erdogan, Atike Pinar
JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2023, 33 (08): : 872 - 878
[30] Clinical validity and clinical utility of Ki67 in early breast cancer
Kreipe, Hans
Harbeck, Nadia
Christgen, Matthias
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14

← 1 2 3 4 5 →